Learning Advanced Analytical Technologies to Expedite the development of Antibody Drug Conjugates

Learn how Light Scattering can benefit your drug development!

A critical step in the development process for an antibody drug conjugate (ADC) is establishing scientifically sound analytical methods that measure key product quality attributes to support pre-clinical activities and downstream clinical release and stability testing. By leveraging key technologies and platform analytical methods, drug developers can expedite an early-phase biologics’ path to IND by removing analytical method development from the critical path.

Join us on an exploration of the analytical characterization required to confidently assess the ID, safety and efficacy of an antibody drug conjugate (ADC). We will start with a practitioners view on the requisite analytics and then shift to several case studies where multiple techniques, from mass spectrometry to light scattering, were used to interrogate these complex protein conjugates.

This webinar promises a comprehensive look at the analytical processes and technologies needed to successfully advance ADC development.

Key learning topics:

• How to assess Identification, safety and efficacy of ADCs

• The requirements for characterisation are for ADCs

• How multiple techniques (such as mass spectrometry and light scattering) can be used together to understand complex protein conjugates.

Who should attend?

• Quality Control and Drug Development Analytical Scientists, Lab Managers and Scientific Directors who are working with ADC characterisation or protein therapeutics in Pharma

Presenter: Eric Miller (Abzena)

Dr. Eric Miller is an accomplished professional with a strong background in analytical chemistry. He has made significant contributions to the biotech industry, particularly through his work on the LabZient™ Analytical Platform.

Eric began his journey as a Scientist at ClinMet. He has worked for Agilent Technologies and Pacira Pharmaceuticals before joining Abzena as Senior Director, Scientific Project Leaders, Analytical.

His expertise lies in addressing the unique needs of biopharmaceuticals.

Presenter: Colette Quinn, Ph.D. (Sr. Business Development Manager, Waters Corporation)

Colette Quinn is a Sr. business development manager in the biopharmaceutical group at Waters Corporation. Her focus is around biophysical solutions and how to integrate biophysical and biochemical approaches to enable a “totality of evidence” based approach to problems.